The Oligonucleotide Synthesis Facility was established in response to the need to provide quality synthetic oligonucleotides to the University of Pittsburgh Cancer Institute (UPCI) members and other investigators in the Pittsburgh research community. The Facility arose from a demonstrated need for oligonulceotides in projects ranging from molecular biology to macromolecular crystallography. The Facility offers both crude and purified oligonucleotides at the 0.05, 0.2 and 1 micromole scales. The yield for each synthesis is assayed and the DNA is dissolved in water, ready for use by the investigator. A DNA Synthesis Advisory Committee, including members of the UPCI, was established to oversee the operation of the Facility. This committee meets yearly to review the performance of the Facility, establish user fees and set protocols to keep the Facility running efficiently. Dr. Graham Hatfull, Chairman of the Department of Biological Sciences, University of Pittsburgh, is the director. He is a renowned molecular biologist and a member of the Molecular and Cellular Oncology Program (need to verify this!). The daily operations such as performing the syntheses, data analysis, quality control and maintenance procedures are carried out by manager, Patricia Wells Gruber and the research specialist, David Close. The Facility can generate high purity oligonucteotidcs quickly and at a reasonable cost. Chemical costs have been progressively discomated in response to the increased volume of orders. The quality, cost and rapid turnaround time make this facility a vital part of the research community.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
United States
Zip Code
Samanta, Suman K; Lee, Joomin; Hahm, Eun-Ryeong et al. (2018) Peptidyl-prolyl cis/trans isomerase Pin1 regulates withaferin A-mediated cell cycle arrest in human breast cancer cells. Mol Carcinog 57:936-946
Velásquez, Celestino; Amako, Yutaka; Harold, Alexis et al. (2018) Characterization of a Merkel Cell Polyomavirus-Positive Merkel Cell Carcinoma Cell Line CVG-1. Front Microbiol 9:713
Stabile, Laura P; Farooqui, Mariya; Kanterewicz, Beatriz et al. (2018) Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer. J Thorac Oncol 13:399-412
Burton, Jenna H; Mazcko, Christina; LeBlanc, Amy et al. (2018) NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. Clin Cancer Res 24:5830-5840
Zang, Yachen; Pascal, Laura E; Zhou, Yibin et al. (2018) ELL2 regulates DNA non-homologous end joining (NHEJ) repair in prostate cancer cells. Cancer Lett 415:198-207
Persky, Michael J; Albergotti, William G; Rath, Tanya J et al. (2018) Positive Margins by Oropharyngeal Subsite in Transoral Robotic Surgery for T1/T2 Squamous Cell Carcinoma. Otolaryngol Head Neck Surg 158:660-666
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090

Showing the most recent 10 out of 1187 publications